KendallDBlondeLMacSXue-SongGHolcombeJOkersonTKimDBholeD. Improvements in cardiovascular risk factors accompanied improved glycemic control and weight reduction in patients with type 2 diabetes treated with exenatide for 3.5 y. Diabetes.2007;56 (Suppl 1): A149.
2.
WolfeGSKingAB. Lack of continued weight loss beyond six months despite continued exenatide treatment. Diabetes.2007;56 (Suppl 1);A548.
3.
LohJAClementSC. Efficacy of exenatide therapy over 12 months in a “real world” setting. Diabetes.2007;56 (Suppl 1): A152.
4.
BuseJBHenryRRHanJKimDDFinemanMSBaronAD; Exenatide-113 Clinical Study Group, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care.2004;27 (11): 2628–35.
